Clinical Report: Patterns of Heart Failure Progression Following Treatment
Overview
This cohort study analyzed LVEF trajectories in patients with HFrEF following guideline-recommended medical treatment. Findings indicate significant gaps in LVEF reassessment and GDMT uptake, with only 33.8% of patients undergoing repeat echocardiograms within 12 months.
Background
Heart failure with reduced ejection fraction (HFrEF) is a major contributor to morbidity and mortality in the adult population. Timely reassessment of left ventricular ejection fraction (LVEF) and adherence to guideline-directed medical therapy (GDMT) are critical for optimizing patient outcomes. However, the actual implementation of these guidelines in clinical practice remains suboptimal.
Data Highlights
Characteristic
Value
Patients with HFrEF
340,305
Median Age
68 years
Median Baseline LVEF
32.1%
Follow-up with Cardiologist
60.4%
Repeat Echocardiogram
33.8%
Key Findings
60.4% of patients had follow-up with a cardiologist or primary care physician within 12 months.
33.8% of patients underwent repeat echocardiogram, with a median time to reassessment of 155 days.
29.2% of patients with repeat echocardiogram had persistent HFrEF, while 62.7% transitioned to heart failure in remission (HFrEFrem).
12-month mortality rates were 21.3% for persistent HFrEF, 14.0% for HFimpEF, and 11.3% for HFrEFrem.
GDMT uptake was modest, with only 45.2% of patients on ACE inhibitors, ARBs, or ARNI at 12 months.
Clinical Implications
The study highlights the need for improved adherence to guidelines regarding LVEF reassessment and GDMT initiation in patients with HFrEF. Clinicians should prioritize regular follow-up and treatment optimization to enhance patient outcomes and reduce mortality risk.
Conclusion
This study underscores significant gaps in the management of HFrEF, particularly in LVEF reassessment and GDMT utilization. Addressing these gaps is essential for improving patient care and outcomes in heart failure.
